Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading on Wednesday. Traders purchased 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the typical volume of 53 put options.

Insider Buying and Selling

In related news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $9.81, for a total value of $97,520,954.94. Following the completion of the transaction, the director now directly owns 20,150,005 shares in the company, valued at $197,671,549.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.63% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MRVI. Bleakley Financial Group LLC increased its position in Maravai LifeSciences by 83.3% during the 4th quarter. Bleakley Financial Group LLC now owns 23,760 shares of the company’s stock valued at $156,000 after purchasing an additional 10,796 shares during the period. Simplicity Solutions LLC raised its stake in Maravai LifeSciences by 83.3% in the fourth quarter. Simplicity Solutions LLC now owns 23,760 shares of the company’s stock worth $156,000 after buying an additional 10,796 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in Maravai LifeSciences by 4.8% during the fourth quarter. Mackenzie Financial Corp now owns 5,169,176 shares of the company’s stock worth $33,858,000 after buying an additional 238,335 shares during the period. VELA Investment Management LLC boosted its position in Maravai LifeSciences by 74.9% during the 4th quarter. VELA Investment Management LLC now owns 74,317 shares of the company’s stock valued at $487,000 after acquiring an additional 31,824 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its holdings in shares of Maravai LifeSciences by 15.4% in the 4th quarter. Handelsbanken Fonder AB now owns 25,500 shares of the company’s stock valued at $167,000 after acquiring an additional 3,400 shares during the period. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Trading Down 6.9 %

Shares of MRVI opened at $8.48 on Friday. Maravai LifeSciences has a twelve month low of $4.52 and a twelve month high of $11.56. The company has a current ratio of 11.32, a quick ratio of 10.47 and a debt-to-equity ratio of 0.71. The company’s fifty day simple moving average is $8.15 and its 200-day simple moving average is $7.98. The company has a market cap of $2.14 billion, a P/E ratio of -8.56 and a beta of 0.02.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter. Maravai LifeSciences had a negative net margin of 47.81% and a negative return on equity of 4.28%. The business had revenue of $73.40 million for the quarter, compared to analysts’ expectations of $71.64 million. During the same quarter in the previous year, the firm earned ($0.06) EPS. Maravai LifeSciences’s revenue was up 6.5% compared to the same quarter last year. As a group, analysts expect that Maravai LifeSciences will post -0.15 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. UBS Group increased their price target on shares of Maravai LifeSciences from $8.50 to $11.00 and gave the stock a “neutral” rating in a research note on Thursday. The Goldman Sachs Group boosted their price objective on shares of Maravai LifeSciences from $7.00 to $8.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Robert W. Baird increased their price target on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, May 9th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.88.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.